118 related articles for article (PubMed ID: 12912688)
1. Prognostic value of S-100-beta serum concentration in patients with uveal melanoma.
Missotten GS; Tang NE; Korse CM; Hurks HM; de Wolff-Rouendaal D; Keunen JE; Jager MJ; Bonfrer JM
Arch Ophthalmol; 2003 Aug; 121(8):1117-9. PubMed ID: 12912688
[TBL] [Abstract][Full Text] [Related]
2. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
3. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
4. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
5. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1).
Barak V; Kaiserman I; Frenkel S; Hendler K; Kalickman I; Pe'er J
Anticancer Res; 2011 Jan; 31(1):345-9. PubMed ID: 21273622
[TBL] [Abstract][Full Text] [Related]
6. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
[TBL] [Abstract][Full Text] [Related]
7. Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2).
Hendler K; Pe'er J; Kaiserman I; Baruch R; Kalickman I; Barak V; Frenkel S
Anticancer Res; 2011 Jan; 31(1):351-7. PubMed ID: 21273623
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
9. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.
Barisione G; Fabbi M; Gino A; Queirolo P; Orgiano L; Spano L; Picasso V; Pfeffer U; Mosci C; Jager MJ; Ferrini S; Gangemi R
JAMA Ophthalmol; 2015 Sep; 133(9):1013-21. PubMed ID: 26068448
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of S-100B protein predict active metastatic disease melanoma.
Expert Rev Mol Diagn; 2002 Nov; 2(6):526. PubMed ID: 12465445
[No Abstract] [Full Text] [Related]
11. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability.
Hahn S; Ugurel S; Hanschmann KM; Strobel H; Tondera C; Schadendorf D; Löwer J; Löwer R
AIDS Res Hum Retroviruses; 2008 May; 24(5):717-23. PubMed ID: 18462078
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma.
Hansson LO; von Schoultz E; Djureen E; Hansson J; Nilsson B; Ringborg U
Anticancer Res; 1997; 17(4B):3071-3. PubMed ID: 9329604
[TBL] [Abstract][Full Text] [Related]
13. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
14. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
[TBL] [Abstract][Full Text] [Related]
16. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
[TBL] [Abstract][Full Text] [Related]
17. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker.
Barak V; Frenkel S; Valyi-Nagy K; Leach L; Apushkin MA; Lin AY; Kalickman I; Baumann NA; Pe'er J; Maniotis AJ; Folberg R
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4399-402. PubMed ID: 17898257
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
19. S-100beta and MIA in advanced melanoma in relation to prognostic factors.
Auge JM; Molina R; Filella X; Bosch E; Gonzalez Cao M; Puig S; Malvehy J; Castel T; Ballesta AM
Anticancer Res; 2005; 25(3A):1779-82. PubMed ID: 16033099
[TBL] [Abstract][Full Text] [Related]
20. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
Schultz ES; Diepgen TL; Von Den Driesch P
Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
